Skip to content

Efficacy of Bone Marrow Mesenchymal Stem Cell in Pulmonary Hemosiderosis

Sun Yat-sen Memorial Hospital

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02985346
Enrollment
100
Registered
2016-12-07
Start date
2017-01-31
Completion date
Unknown
Last updated
2016-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Idiopathic Pulmonary Hemosiderosis

Keywords

Idiopathic pulmonary hemosiderosis, Bone marrow mesenchymal stem cells

Brief summary

Pulmonary hemosiderosis (PH) is a pulmonary hemosiderin deposition which caused by alveolar capillary hemorrhage. PH is easy to recurrent and can lead to pulmonary fibrosis and insufficiency if the disease was poor controlled. Steroid is the most common drug that was administered in acute phase of the disease. However, considered the side-effects, steroid is not suitable for long-time maintenance. Therefore, it is necessary to explore a new therapy. Bone marrow mesenchymal stem cells (BMSC) are a kind of adult stem cells with high self-renewal and multi-directional differentiation potential in bone marrow. It has become a hot topic in immunosuppressive and tissue repair therapy in recent years. To date, homing, colonization and differentiation of BMSCs in the lung have been observed in animal models of pulmonary hypertension, radiation pneumonitis and pulmonary fibrosis. It had been reported that BMSC transplantation in acute lung injury in mice, inflammation of lung injury can significantly improve. The aim of this study is to explore the effect of BMSC on PH and its mechanism, and to explore a new way to promote the repair of IPH. It is expected to improve the status of IPH therapy in children, especially improve the prognosis of refractory PH.

Interventions

BIOLOGICALBone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis

Sponsors

Sun Yat-sen University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Months to 18 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients diagnosed with Pulmonary hemosiderosis at an age less than 18 years.

Exclusion criteria

* Patients who cannot finish the established causes or die during the causes.

Design outcomes

Primary

MeasureTime frame
Complete remission3-6 months

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026